Company news

InflaRx N.V. news in 2026

InflaRx N.V.'s news releases, calls and decks from 2026, newest first.

View company

InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day

November 3, 2026

InflaRx Announces November Investor Events

October 27, 2026

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

October 22, 2026

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

October 2, 2026

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President and Global Head of Clinical Development

October 2, 2026

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

October 1, 2026

InflaRx to Host Virtual Capital Markets Day

September 21, 2026

InflaRx Announces Participation in September Investor Conferences

August 20, 2026

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

August 6, 2026

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

July 30, 2026

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

June 30, 2026

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

May 8, 2026

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

May 6, 2026

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

May 4, 2026

InflaRx to Report First Quarter 2026 Results on May 7, 2026

May 1, 2026

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

April 8, 2026

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

March 31, 2026

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

March 30, 2026

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

March 18, 2026

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

March 17, 2026

InflaRx to Report Full Year 2025 Results on March 19, 2026

March 12, 2026

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

February 26, 2026

InflaRx Announces Participation in February Investor Conferences

January 29, 2026

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

January 8, 2026

Decks in 2026